The label-context reader

Four questions to keep beside the label

Four fixed examples follow the words and quantities in public records. Every field remains open; topic links move within this page. Nothing asks for personal answers or calculates an amount.

This reader explains published labels and evidence limits; it does not assess diet, swallowing, symptoms, allergies or medicine combinations. Quantities describe documents, not instructions for intake. The examples cannot authenticate a supplied lot, select a supplement or convert blend mass into dietary-fiber grams. Product and order details belong with the seller or manufacturer; individual health and medicine questions belong with a qualified healthcare professional. This publication and seller-support channels are not emergency care.

What does the blend number describe?

What the record says

Full House’s published panel assigns 1,525 mg to a proprietary blend containing konjac root extract, psyllium husk powder, glucomannan and apple cider vinegar powder. The facts serving is two capsules. Individual component amounts and a separate dietary-fiber gram declaration are not provided.

What the source covers

FDA’s labeling guidance explains the declaration of a proprietary-blend total. Its dietary-fiber guidance separately explains which materials may count in a nutrient declaration. Neither source supplies the missing quantitative fiber result for Full House or confirms compliance of a specific bottle.

What remains unresolved

The total cannot be treated as each ingredient’s weight, a stated dietary-fiber amount or a contribution to an individual’s food intake. The available records do not establish a conversion that fills those gaps. A label observation is not an intake recommendation.

A question for the right professional

For the manufacturer: is there a current dietary-fiber declaration or specification for this exact finished formula, and what document supports it? A dietitian or clinician can address a person’s food and health context; the seller’s blend total cannot settle that assessment.

Return to label topics

Is the research preparation the sold formula?

What the record says

Full House names glucomannan within a multicomponent blend. The published 2013 trial studied a specified glucomannan capsule preparation against placebo, with 53 randomized adults and 47 completers. It did not study Full House, SW993 or NOW’s reviewed psyllium capsules.

What the source covers

The full trial reports how its study material was prepared and checked. NIH’s evidence overview explains that ingredient studies and combinations can differ in their effects. Study-material analysis belongs to that preparation; it is not laboratory verification of any bottle reviewed on this site.

What remains unresolved

The commercial blend’s individual amounts and the connection to the trial preparation remain unestablished. Recognizing an ingredient name does not show that the exact combination produces the same outcomes or that a particular person resembles the selected study population.

A question for the right professional

For a clinician or pharmacist discussing the evidence: does the available research address the actual preparation and the concern being considered? For the manufacturer: is there research on the complete current formula, with a clearly identified population, comparator and measured outcome?

Return to label topics

Which outcome does fullness wording establish?

What the record says

Full House’s current offer discusses fullness support while explicitly saying it is not a weight-loss product or appetite suppressant. In the glucomannan trial, body-weight change and reported hunger or fullness were separate outcomes; the investigators found no significant between-group differences in those efficacy measures.

What the source covers

The trial’s observations cover its specified preparation, selected adults and eight-week follow-up. The result is neither a favorable claim for the reviewed blend nor proof that every fiber preparation has identical effects. The seller’s exclusion of weight-loss claims also remains part of its published offer.

What remains unresolved

A fullness phrase does not establish a measured change in food intake or body weight. Discomfort is not a substitute endpoint or evidence of benefit. Full House’s own page directs severe, persistent or concerning symptoms to a healthcare professional and rejects treating GLP-1 side effects.

A question for the right professional

For the healthcare professional addressing the underlying concern: which outcome would actually matter in this situation, and what evidence addresses it? A seller can clarify wording, but a marketing timeline cannot diagnose symptoms or determine whether a supplement is appropriate.

Return to label topics

Do the page and package tell the same story?

What the record says

NOW’s current 500 mg capsule page says the product may contain traces of sesame. Its linked 200-capsule bottle artwork includes sesame in a not-manufactured-with list and separately qualifies the manufacturing facility. Swanson’s selected SW993 record declares wheat.

What the source covers

These are exact manufacturer-published records inspected on September 28, 2026. They describe online versions, not an authenticated delivered lot. The ingredient and allergen statements should remain visible with their sources instead of being combined into a more reassuring declaration.

What remains unresolved

The public documents do not determine which NOW sesame wording applies to a supplied container. A vegan description, shared plant name or recognizable bottle image cannot resolve an allergy question or prove that a different package is the same formulation.

A question for the right professional

For the manufacturer: which current label and allergen declaration apply to this item and supplied lot? For a clinician or pharmacist: what does the confirmed declaration mean for an individual’s circumstances? This reader cannot verify a package or provide allergy clearance.

Return to label topics